Carcinoma, Renal Cell, Carcinoma, Renal Cell (Advanced)
Conditions
Keywords
Advanced Renal Cell Carcinoma
Brief summary
Renal cell carcinoma accounts for roughly 3 % of all cancer. It is a rather aggressive cancer type, which means that patients who present with an advanced disease have a rather poor prognosis. When this study has been started the standard therapy for patients has been cytokines, which might be accompanied by significant toxicities or might fail the therapeutic goal. In these cases sorafenib can be a feasible therapeutic option. This non-interventional study has been created and is being conducted to collect clinical data on the patients' therapy with sorafenib in an everyday treatment schedule. The main goal of this study focuses on patient characteristics and tumor status in RCC treated with sorafenib as well as the treatment duration and safety of sorafenib under everyday treatment conditions.
Interventions
Patients with a diagnosis of advanced RCC
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with diagnosis of advanced RCC and decision taken by the investigator to prescribe Sorafenib
Exclusion criteria
*
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor status | After about 3, 6, 9 and 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Treatment duration | At end of study after about 12 months |
| Safety of sorafenib treatment | At every documented visit for about 12 months |
| Progression-free survival | Calculation at end of study after about 12 months |
| Status of Metastases | After about 3, 6, 9 and 12 months |
| Performance status (ECOG) | After about 3, 6, 9 and 12 months |
Countries
Argentina, Austria, China, Colombia, Czechia, France, Germany, Greece, Indonesia, Mexico, Netherlands, Philippines, Poland, Russia, Slovakia, Slovenia, South Korea, Sweden
Outcome results
None listed